Science 37 and Catalent partner to enhance at-home delivery of clinical trial medications, expanding patient access and improving enrollment.
Quiver AI Summary
Science 37 and Catalent have announced a strategic partnership aimed at transforming the delivery of investigational medicinal products (IMPs) directly to patients' homes for clinical trials. This collaboration enhances Science 37’s Direct-to-Patient Clinical Trial Site model by utilizing Catalent’s logistics expertise to ensure timely and secure delivery of study medications, allowing broader patient participation from diverse locations. The partnership has already enrolled nearly 1,700 patients across 17 studies, demonstrating significant improvements in enrollment speed and access to clinical research. Both companies emphasize their commitment to creating a more inclusive and efficient clinical trial process, ultimately driving faster drug development while maintaining quality standards.
Potential Positives
- Science 37 has formed a strategic partnership with Catalent, enhancing their Direct-to-Patient Clinical Trial Site model, which is pivotal in expanding patient access to clinical trials.
- The collaboration has successfully enrolled nearly 1,700 patients across 17 studies, showcasing the efficiency and effectiveness of the Direct-to-Patient model.
- By streamlining the clinical trial process and offering an end-to-end solution under a single contract, Science 37 can improve enrollment speed and retention rates while reaching underserved populations.
- The partnership positions Science 37 as a leader in transforming clinical research, emphasizing inclusivity and patient-centered approaches, which may appeal to sponsors and investors alike.
Potential Negatives
- None
FAQ
What is the partnership between Science 37 and Catalent about?
The partnership aims to redefine how investigational medicinal products are delivered directly to patients' homes for clinical trials.
How does the Direct-to-Patient model work?
The model allows patients to participate in clinical research from their homes, supported by efficient shipping and logistics from Catalent.
What are the benefits of this collaboration for clinical trials?
The collaboration improves enrollment speed, retention rates, and expands access to underserved populations in clinical research.
How many patients have been enrolled through this partnership?
The partnership has enrolled nearly 1,700 patients across 17 studies, averaging 26% enrollment at each Direct-to-Patient Site.
Where can I learn more about Science 37 and Catalent?
Visit www.science37.com and www.catalent.com for more information on their partnership and clinical research solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, and Catalent ® , a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research.
Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by providing reliable, efficient shipping and logistics services for study medications, ensuring rapid and secure delivery of IMPs across geographies and enabling patients to participate in clinical research from the comfort of their homes, regardless of their location.
“Catalent’s expertise in direct-to-patient logistics is a key enabler of our mission to expand access to clinical trials,” said Tyler Van Horn, CEO at Science 37. “By removing geographic barriers, we’re not only reaching more diverse patient populations, we’re also driving faster enrollment and generating high-quality data that helps bring treatments to market sooner.”
Science 37 and Catalent have partnered to refine the IMP supply chain for at-home trial participation and visit execution. Across 17 studies, Catalent and Science 37's partnership enrolled nearly 1,700 patients by bringing clinical trials directly into the home, enrolling an average 26% of the total study population in a single Direct-to-Patient Site, with 9 patients enrolled per month or the equivalent of more than 15 brick-and-mortar locations in each instance. To date, the partnership has delivered over 6,400 shipments to study participants.
This integrated solution offers sponsors an end-to-end clinical trial site under a single contract and budget, streamlining operations, improving enrollment speed and retention rates, and expanding access to underserved and geographically dispersed populations.
“Our partnership with Science 37 transforms the clinical trial experience, bringing research directly to participants while preserving the rigor and efficiency on which sponsors rely,” said Ricky Hopson, President, Clinical and Specialty Services, and Chief of Staff at Catalent. “Together, we’re advancing a more inclusive and patient-centered future for clinical research, without compromising precision or quality.”
To learn more about how Science 37 and Catalent are transforming clinical research, visit www.science37.com and www.catalent.com .
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
For more information, visit www.catalent.com .
About Science 37
Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes for all. Our solutions empower life sciences companies to reach diverse populations beyond traditional means of conducting clinical research. To learn more, visit www.science37.com or email [email protected] .
To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies .
Media Inquiries
Science 37
[email protected]
